EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review

Masaoki Ito, Yoshihiro Miyata, Morihito Okada

Translational Oncology · 2023-05 · 31 · 101634

DOI: 10.1016/j.tranon.2023.101634 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Translational Oncology, 2023-05. Verfasst von Masaoki Ito und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Research Institute for Radiation, Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 73…. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review aimed to shed light on the trend of current clinical trials of non-coding RNA (ncRNA)-based therapeutics for malignant diseases. We conducted a database search for published literature and ongoing clinical trials using PubMed, clinicaltrials.gov, and University Medical Information Network (UMIN) clinical trial registry. To ensure that our review was based on up-to-date clinical trials, we limited our search to literature published within the last five years (January 2017-September 2022). Furthermore, due to the "clinical" nature of our review, we focused only on studies involving human participants. Among ncRNAs, microRNAs have been extensively explored in observational studies of malignant diseases as potential diagnostic markers and prognostic predictors, as well as for their therapeutic monitoring and profiling capabilities. As therapeutic agents, microRNA or siRNA were estimated in interventional human clinical trials and showed promising outcomes; however, the number of trials was small. Evidence and ongoing clinical trials in which ncRNAs other than microRNA or siRNA have been evaluated for their potential as therapeutic agents are limited. Here, we summarized microRNA as a potential therapeutic agent in malignant diseases, but most of the current evidence suggests that it is useful as a potential biomarker. siRNA is also a promising ncRNA technique in cancer, however more data from clinical trials are warranted for clinical use.

Schlagwörter

Stichwörter der Autor:innen

CancerClinical trialMalignant diseasesMicroRNANon-coding RNARNA interference

Autor:innen und Institutionen

  • Department of Surgical Oncology, Research Institute for Radiation, Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Electronic address: itooo_m@yahoo.co.jp.
  • Department of Surgical Oncology, Research Institute for Radiation, Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Department of Surgical Oncology, Research Institute for Radiation, Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Electronic address: morihito1217@gmail.com.

Zitieren

APA

Ito, M., Miyata, Y., & Okada, M. (2023). Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review. Translational Oncology, 31, 101634. https://doi.org/10.1016/j.tranon.2023.101634

Vancouver

Ito M, Miyata Y, Okada M. Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review. Translational Oncology. 2023;31:101634. doi:10.1016/j.tranon.2023.101634

BibTeX
@article{Ito2023,
  author = {Ito, Masaoki and Miyata, Yoshihiro and Okada, Morihito},
  title = {Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review},
  journal = {Translational Oncology},
  year = {2023},
  volume = {31},
  pages = {101634},
  doi = {10.1016/j.tranon.2023.101634}
}
Kostenlos starten →